Apparent efficacy of κ-opioid receptor ligands on serum prolactin levels in rhesus monkeys

European Journal of Pharmacology

Volumn 383, Issue 3, 1999, Pages 305-309

  Butelman, Eduardo R ^a   Harris, Todd J ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Bremazocine; Efficacy; Nalmefene; Prolactin; Rhesus monkey; U50,488

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BREMAZOCINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; NALMEFENE; NALORPHINE; PROLACTIN;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RHESUS MONKEY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS; ANIMALS; BIOLOGICAL MARKERS; FEMALE; LIGANDS; MACACA MULATTA; NARCOTICS; PROLACTIN; RECEPTORS, OPIOID, KAPPA;

EID: 0032764055     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00640-8     Document Type: Article

References (20)

1. Butelman E.R., Harris T., Perez A., Kreek M.J. Effects of systemically administered dynorphin A(1-17) in rhesus monkeys. J. Pharmacol. Exp. Ther. 290:1999;678-686.
2. 2 opioid binding sites in rats, guinea pigs, monkeys and humans. NeuroReport. 9:1998;2523-2525.
3. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244:1988;1067-1080.
4. Dykstra L.A., Woods J.H. A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J. Pharmacol. Methods. 15:1986;263-269.
5. France C.P., Gerak L.R. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J. Pharmacol. Exp. Ther. 270:1994;992-999.
6. France C.P., Medzihradsky F., Woods J.H. Comparison of kappa opioids in rhesus monkeys: behavioral effects and receptor affinities. J. Pharmacol. Exp. Ther. 268:1994;47-58.
7. Gilbeau P.M., Hosobuchi Y., Lee N.M. Dynorphin effects on plasma concentrations of anterior pituitary hormones in the nonhuman primate. J. Pharmacol. Exp. Ther. 238:1986;974-977.
8. Kreek M.J., Schluger J., Borg L., Gunduz M., Ho A. Dynorphin A(1-13) causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J. Pharmacol. Exp. Ther. 288:1999;260-269.
9. Kuzmin A.V., Gerrits M.A.F.M., Van Ree J.M. κ-opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naïve rats. Eur. J. Pharmacol. 358:1998;197-202.
10. Mello N.K., Negus S.S. Effects of kappa opioid agonists on cocaine- and food-maintained responding in rhesus monkeys. J. Pharmacol. Exp. Ther. 286:1998;812-824.
11. Moore K.E., Lookingland K.J. Dopaminergic neuronal systems in the hypothalamus. Bloom F.E., Kupfer D.J. Psychopharmacology: the fourth generation of progress. 1995;245-256 Raven Press, New York.
12. Nestby P., Schoffelmeer A.N.M., Homberg J.R., Wardeh G., De Vries T.J., Mulder A.H., Vanderschuren L.J.M.J. Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference. Psychopharmacology. 142:1999;309-311.
13. Pande A.C., Pyke R.E., Greiner M., Wideman G.L., Benjamin R., Pierce M.W. Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin. Neuropharmacol. 19:1996;451-456.
14. Pfeiffer A., Pasi A., Mehraein P., Herz A. Psychotomimesis mediated by k opiate receptors. Science. 233:1981;774-776.
15. Pfeiffer A., Braun S., Mann K., Meyer H.D., Brantl V. Anterior pituitary responses to a kappa opioid agonist in man. J. Clin. Endocrinol. Metab. 62:1986;181-185.
16. Remmers A.E., Clark M.J., Mansour A., Akil H., Woods J.H., Medzihradsky F. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J. Pharmacol. Exp. Ther. 288:1999;827-833.
17. Shippenberg T.S., Lefevour A., Heidbreder C. Kappa-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J. Pharmacol. Exp. Ther. 276:1996;545-554.
18. Stein C., Millan M.J., Shippenberg T.S., Peter K., Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J. Pharmacol. Exp. Ther. 248:1989;1269-1275.
19. Ur E., Wright D.M., Bouloux M.G., Grossman A. The effects of spiradoline (U62,066E), a k-opioid receptor agonist, on neuroendocrine function in man. Br. J. Pharmacol. 120:1997;781-784.
20. 35S] GTP gamma S binding to membranes: determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 282:1997;676-684.